Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Killing the Last 0.1%: Targeting Cancer Persister Cells June 15, 2026
- Phase III PrTK03 Trial Results: Aglatimagene Besadenovec (CAN-2409) Improves Survival in Localized Prostate Cancer June 15, 2026
- Newsletter 24/2026 June 14, 2026
- Phase 2 Trial for 61Cu-NU101 vs 18F-Piflufolastat in Metastatic Prostate Cancer June 11, 2026
Penetrium: A Breakthrough in Overcoming Cold Tumors and Metastatic Cancer
/in Preclinical Research/by MaxPioglitazone: Diabetes Drug Shows Promise for Treating Prostate Cancer
/in Drug repurposing, Preclinical Research/by MaxUPDATE: JANX007 Starts Phase 1b Expansion Studies
/in Clinical Trial, Metastatic, Phase 1/by MaxNTS071 to Target p53 Y220C Mutation in Solid Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxA New Insight From the ARANOTE Trial for mHSPC
/in Post-hoc/by MaxSetback in Prostate Cancer Trial: CAPItello-280 Study for Truqap Discontinued
/in Clinical Trial, Metastatic, Phase 3/by MaxPrecision in Action: How Logic-Gating Redefines Targeted Therapy
/in Not PCa related/by MaxUPDATE: ATNM-400 a Promising Antibody Radioconjugate Delivering 225 Ac
/in Preclinical Research/by Max